相关临床试验
6
6 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
6
100.0%
暂无批准数据
- Clinical operations leaders argue that sponsors who treat a signed work order as a substitute for leadership are the architects of their own trial failures. - Tufts CSDD data shows only one in five sponsors rate their oversight processes as highly effective, exposing a widespread governance deficit. - The Applied Therapeutics case demonstrates that delegation does not transfer accountability, as the FDA warning letter went to the sponsor, not the CRO. - Experts recommend early CRO engagement as a "thought partner" during protocol design to reduce costly amendments and enrollment failures.
- Cycle Group Holdings Limited announced a definitive agreement to acquire Applied Therapeutics for $0.088 per share plus contingent value rights worth up to $0.40 per share. - The acquisition focuses on advancing govorestat, Applied's lead CNS-penetrant aldose reductase inhibitor targeting rare metabolic diseases including Classic Galactosemia and CMT-SORD. - Applied Therapeutics received an $8.5 million promissory note from Cycle to fund operations, as the company would otherwise be unable to continue activities for more than a limited number of days. - The transaction is expected to close in the first quarter of 2026, subject to customary closing conditions including tender of a majority of outstanding shares.
- Applied Therapeutics shares plummeted 51% following an unsuccessful FDA meeting regarding govorestat for Charcot-Marie-Tooth sorbitol dehydrogenase deficiency treatment. - The FDA meeting failed to establish a clear regulatory pathway forward, including potential accelerated approval options for the rare genetic disorder therapy. - The company awaits official FDA meeting minutes to determine next steps while maintaining commitment to addressing unmet needs in CMT-SORD patients. - CMT-SORD represents a progressive, debilitating hereditary neuropathy affecting peripheral nerves and motor neurons with significant unmet medical need.
- Applied Therapeutics will present full 12-month results from the Phase 3 INSPIRE trial of govorestat for SORD Deficiency at the Peripheral Nerve Society 2025 Annual Meeting in Edinburgh, Scotland. - The presentation will include new topline 18-month and 24-month data from the double-blind, placebo-controlled registrational trial, extending beyond the previously reported 12-month results. - Govorestat, a CNS-penetrant Aldose Reductase Inhibitor, has received multiple regulatory designations including Orphan Drug status from both FDA and EMA for treating rare diseases including CMT-SORD.
- Applied Therapeutics received a Complete Response Letter from the FDA for its govorestat NDA due to deficiencies found during a preapproval inspection. - The FDA issued a Warning Letter citing dosing errors and data deletion by a third-party vendor in the ACTION-Galactosemia Kids trial. - Shareholder lawsuits have been filed against Applied Therapeutics, alleging the company misled investors regarding govorestat's approval prospects. - The company's founder and CEO, Dr. Shoshana Shendelman, resigned amidst these challenges, highlighting the severity of the regulatory setbacks.
- The FDA has rejected Applied Therapeutics' marketing application for govorestat for the treatment of galactosaemia due to deficiencies in the clinical application. - The agency also issued a warning letter regarding a clinical trial of govorestat, citing issues with electronic data capture and access to records. - Applied Therapeutics plans to request a meeting with the FDA to discuss requirements for potential resubmission or appeal of the decision. - Govorestat is also being developed for SORD deficiency, with a potential approval filing planned for the first quarter of 2025.
- The FDA issued a Complete Response Letter for govorestat, citing deficiencies in the clinical application for treating Classic Galactosemia. - Govorestat demonstrated rapid galactitol reduction and clinical benefits in pediatric patients during Phase 3 trials, showing a favorable safety profile. - Applied Therapeutics plans to meet with the FDA to discuss requirements for NDA resubmission or appeal, while continuing govorestat's development for SORD Deficiency. - The NDA submission for govorestat in treating Sorbitol Dehydrogenase (SORD) Deficiency is expected in early 2025, independent of the Galactosemia review.
- Applied Therapeutics is facing a class-action lawsuit alleging misleading statements about the Phase 3 INSPIRE trial for govorestat, a drug for Galactosemia. - The FDA issued a Complete Response Letter for govorestat's New Drug Application, citing deficiencies in the clinical application, which led to a stock price drop. - The lawsuit claims Applied Therapeutics concealed issues such as electronic data capture problems and dosing errors during the govorestat trial. - Leadership changes at Applied Therapeutics include John Johnson as executive chairman and Les Funtleyder as interim CEO, following Shoshana Shendelman's departure.
- Applied Therapeutics appoints John H. Johnson as Executive Chairman, leveraging his extensive experience to drive growth and value creation. - Les Funtleyder steps in as Interim CEO while maintaining his role as CFO, ensuring continuity and focus on pipeline advancement. - The company is re-evaluating its regulatory strategy for govorestat, including NDA submission for SORD Deficiency after Q1 2025. - Applied Therapeutics is withdrawing its MAA application in Europe for govorestat in Classic Galactosemia, pending further data acquisition.
- The FDA issued a Complete Response Letter (CRL) for Applied Therapeutics' govorestat in treating galactosemia, a decision deemed 'unexpected and disappointing'. - The CRL's lack of specifics obscures the future regulatory path for govorestat, potentially necessitating an additional clinical trial. - William Blair maintains an 'Outperform' rating on Applied Therapeutics, suggesting a Type-A meeting with the FDA could clarify the path forward despite this setback.
